

Clerk of the House of Representatives  
 Legislative Resource Center  
 B-106 Cannon Building  
 Washington, DC 20515

Secretary of the Senate  
 Office of Public Records  
 212 Hart Building  
 Washington, DC 20510

RECEIVED  
 CLERK OF THE SENATE

00 AUG 17 PM 1:59

## LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required To Complete This Page

1. Registrant Name Hyman, Phelps & McNamara, P.C.			
2. Address <input type="checkbox"/> Check if different than previously reported 700 13th Street, NW, # 1200			
3. Principal Place of Business (if different from line 2) City: Washington State/Zip (or Country) DC, 20005			
4. Contact Name Douglas B. Farquhar	Telephone (202) 737 - 9624	E-mail (optional)	5. Senate ID # 19035-51
7. Client Name <input type="checkbox"/> Self Medeva Pharmaceuticals, Inc.			6. House ID # 33250004

TYPE OF REPORT 8. Year 2000 Midyear (January 1-June 30)  OR Year End (July 1-December 31)

9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report  ⇨ Termination Date \_\_\_\_\_

11. No Lobbying Activity

### INCOME OR EXPENSES - Complete Either Line 12 OR Line 13

<p><b>12. Lobbying Firms</b></p> <p>INCOME relating to lobbying activities for this reporting period was:</p> <p>Less than \$10,000 <input checked="" type="checkbox"/></p> <p>\$10,000 or more <input type="checkbox"/> ⇨ \$ _____  <small>Income (nearest \$20,000)</small></p> <p>Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).</p>	<p><b>13. Organizations</b></p> <p>EXPENSES relating to lobbying activities for this reporting period were:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input type="checkbox"/> ⇨ \$ _____  <small>Expenses (nearest \$20,000)</small></p> <p><b>14. REPORTING METHOD.</b> Check box to indicate expense accounting method. See instructions for description of options.</p> <p><input type="checkbox"/> Method A. Reporting amounts using LDA definitions only</p> <p><input type="checkbox"/> Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code</p> <p><input type="checkbox"/> Method C. Reporting amounts under section 162(e) of the Internal Revenue Code</p>
---	---

Signature D. B. Farquhar

Printed Name and Title Douglas B. Farquhar, Member

LD-2 (REV. 6/98)

PAGE 1 of 2

Hyman, Phelps & McNamara, P.C.  
 Registrant Name \_\_\_\_\_ Client Name Medeva Pharmaceuticals, Inc.

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code MED (one per page)

16. Specific lobbying issues

Amending the Controlled Substances Act (21 U.S.C. 953) to allow controlled substances exported from the United States, as permitted by the Drug Enforcement Administration, to be re-exported to specified European countries after packaging, processing or warehousing in the country to which the substances were first exported.

17. House(s) of Congress and Federal agencies contacted  Check if None

Staff members for House of Representative Committees.  
 Staff members in offices of Representatives and Senators  
 Drug Enforcement Agency  
 Department of Justice

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
James R. Phelps		<input type="checkbox"/>
John A. Gilbert		<input type="checkbox"/>
Douglas B. Farquhar		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

Foreign entity with manufacturing facilities in the United States seeks ability to export controlled substances for re-export after warehousing, reprocessing or repackaging.

Signature *D. B. Farquhar* Date 9/11/00

Printed Name and Title Douglas B. Farquhar, Member